Breeze Meds vs Ro
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Breeze Meds
Best for compounded GLP-1 access with named prescribers and 4-pharmacy networkStarting at $199/mo
Ro
Best for broadest GLP-1 formulary including Foundayo on day-one of launchStarting at $149/mo
Side-by-Side Comparison
| Feature | Breeze Meds | Ro |
|---|---|---|
| Overall Score | 7.3/10 | ✓7.9/10 |
| Starting Price | $199/mo | ✓$149/mo |
| Editorial Rating | 3.7 ★ /5 | ✓4 ★ /5 |
| Features | 6 features | ✓7 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | — |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Breeze Meds
Pros
- ✓Available in all 50 US states
- ✓LegitScript certified seal displayed in footer
- ✓Publicly named medical team with NPI numbers: Dr. Ana Lisa Carr MD (NPI 1689841744) and Dr. Kelly Tenbrink MD (NPI 1346482684)
- ✓Four named 503A pharmacy partners: Belmar Pharma Solutions, Strive Pharmacy, Epiq Scripts, Casa Pharma Rx
- ✓Both injectable and oral formats available for semaglutide and tirzepatide
- ✓No FDA warning letters or litigation on record as of 2026-04-09
Cons
- ✗Runs on the same Lion MD clinician network and the same 4 compounding pharmacies as Care Bare Rx and Synergy Rx — if you're comparing the three brands, be aware you're comparing three storefronts on top of one underlying operation, not three independent providers
- ✗Compounded medications are not FDA-approved
- ✗Compounded vs. brand-name drug sourcing is ambiguously disclosed on the product pages
- ✗Terms of Service page returns a 404 (Privacy Policy is present) — a procedural transparency gap
- ✗Insurance acceptance is not clearly disclosed beyond FSA/HSA eligibility
Ro
Pros
- ✓Most comprehensive GLP-1 formulary in telehealth — compounded semaglutide, brand-name Wegovy, brand-name Zepbound, and the new oral Foundayo (orforglipron) all available on one platform
- ✓Among the first telehealth providers to launch Foundayo on day one of the Lilly partner rollout (April 9 2026)
- ✓Clinician-led plan selection — 'patients connect with a licensed provider and, if appropriate, determine which GLP-1 is the best option based on their insurance coverage, the cost, and their unique clinical needs and health goals'
- ✓Nationwide delivery network — Ro reports having served patients in 'nearly every single county in the United States, including 99% of primary care deserts'
- ✓Both cash-pay and insurance-eligible options under one roof
Cons
- ✗Foundayo on Ro requires a recurring membership in addition to the $149/mo cash drug price — total monthly cost is higher than the headline number
- ✗Specific Foundayo dose-tier pricing above the lowest dose not publicly disclosed in the launch announcement — needs intake to confirm
- ✗State availability and pharmacy partners not itemized publicly — requires signup intake to verify
- ✗Like all telehealth GLP-1 providers, Ro charges separately for the program (membership) and the medication; users sometimes confuse the bundled vs. unbundled pricing models
Our Verdict
Ro edges out Breeze Meds with a higher overall score of 7.9/10 and is particularly strong for broadest GLP-1 formulary including Foundayo on day-one of launch. Breeze Meds remains a solid alternative, especially if you're looking for compounded GLP-1 access with named prescribers and 4-pharmacy network.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.